Neutrophil Gelatinase-associated Lipocalin at ICU Admission Predicts for Acute Kidney Injury in Adult Patients

Department of Intensive Care Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
American Journal of Respiratory and Critical Care Medicine (Impact Factor: 13). 10/2010; 183(7):907-14. DOI: 10.1164/rccm.200908-1214OC
Source: PubMed


Measured at intensive care unit admission (ICU), the predictive value of neutrophil gelatinase-associated lipocalin (NGAL) for severe acute kidney injury (AKI) is unclear.
To assess the ability of plasma and urine NGAL to predict severe AKI in adult critically ill patients.
Prospective-cohort study consisting of 632 consecutive patients.
Samples were analyzed by Triage immunoassay for NGAL expression. The primary outcome measure was occurrence of AKI based on Risk-Injury-Failure (RIFLE) classification during the first week of ICU stay. A total of 171 (27%) patients developed AKI. Of these 67, 48, and 56 were classified as RIFLE R, I, and F, respectively. Plasma and urine NGAL values at ICU admission were significantly related to AKI severity. The areas under the receiver operating characteristic curves for plasma and urine NGAL were for RIFLE R (0.77 ± 0.05 and 0.80 ± 0.04, respectively), RIFLE I (0.80 ± 0.06 and 0.85 ± 0.04, respectively), and RIFLE F (0.86 ± 0.06 and 0.88 ± 0.04, respectively) and comparable with those of admission estimated glomerular filtration rate (eGFR) (0.84 ± 0.04, 0.87 ± 0.04, and 0.92 ± 0.04, respectively). Plasma and urine NGAL significantly contributed to the accuracy of the "most efficient clinical model" with the best four variables including eGFR, improving the area under the curve for RIFLE F prediction to 0.96 ± 0.02 and 0.95 ± 0.01. Serial NGAL measurements did not provide additional information for the prediction of RIFLE F.
NGAL measured at ICU admission predicts the development of severe AKI similarly to serum creatinine-derived eGFR. However, NGAL adds significant accuracy to this prediction in combination with eGFR alone or with other clinical parameters and has an interesting predictive value in patients with normal serum creatinine.

Download full-text


Available from: Hilde De Geus
  • Source
    • "All research staff obtained formal training in the measurement of wbNGAL and calibration of the Triage® MeterPro. Patients with a wbNGAL concentration that exceeded the upper limit of detectability for the assay (>1300 ng/mL) were assigned an wbNGAL value of 1300 ng/mL for the purpose of conducting the analyses as done in previous studies [16] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Acute kidney injury is common in intensive care units and is associated with increased morbidity and mortality. We evaluated the ability of whole-blood neutrophil gelatinase-associated lipocalin (wbNGAL) to predict mortality and need for renal replacement therapy (RRT) in critically ill patients with kidney dysfunction. Methods: We prospectively enrolled adult patients in 5 Canadian intensive care units. We measured wbNGAL at the time of enrollment to determine whether NGAL concentration could predict the primary composite outcome of death or need for RRT by day 30 in addition to other secondary outcomes. Results: We recruited 234 patients; 227 were included in the analysis. In a multivariable model, wbNGAL did not predict 30-day mortality or need for RRT (odds ratio, 1.05; 95% confidence interval, 0.99-1.12). Neutrophil gelatinase-associated lipocalin was similar in patients who died (654 [303-1180] ng/mL) vs those who survived (541.5 [255.5-1080] ng/mL, P = .26) by 90 days. Whole-blood NGAL poorly predicted the primary outcome (area under receiver operator curve, 0.65; 95% confidence interval, 0.58-0.73). Conclusions: In a cohort of critically ill patients with abnormal kidney function, wbNGAL was not effective in the prediction of death or RRT within 30 days. These data do not support the use of this biomarker for the detection of clinical outcomes in this population.
    Full-text · Article · Sep 2015 · Journal of critical care
  • Source
    • "Volume 5 @BULLET Issue 6 @BULLET 1000221 J Nephrol Ther ISSN: 2211-0959 JNT, an open access journal AKI with high sensitivity 1-2 days before the serum creatinine levels increases[9,10]. Current studies have shown the worth of NGAL in identifying patients with AKI[11], i.e. it differentiates between acute pyelonephritis and lower UTI[12], and diagnoses UTI in adults in ICU settings[13]. Therefore, NGAL can be considered as a good marker for renal function and inflammation, providing more specificity for the diagnosis of AKI. "

    Preview · Article · Jan 2015
  • Source
    • "Approximately 30% of critically ill patients admitted to an intensive care unit (ICU) develop acute kidney injury (AKI) [1]. Biomarker neutrophil gelatinase-associated lipocalin (NGAL) is associated with the development of AKI, the need for dialysis, and mortality [1-4]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Previous pharmacokinetic trials suggested that 40 mg subcutaneous enoxaparin once daily provided inadequate thromboprophylaxis for intensive care unit patients. Critically ill patients with acute kidney injury are at increased risk of venous thromboembolism and yet are often excluded from these trials. We hypothesized that for critically ill patients with acute kidney injury receiving continuous renal replacement therapy, a dose of 1 mg/kg enoxaparin subcutaneously once daily would improve thromboprophylaxis without increasing the risk of bleeding. In addition, we seek to utilize urine output prior to discontinuing dialysis, and low neutrophil gelatinase-associated lipocalin in dialysis-free intervals, as markers of renal recovery. Methods/design: In a multicenter, double-blind randomized controlled trial in progress at three intensive care units across Denmark, we randomly assign eligible critically ill adults with acute kidney injury into a treatment (1 mg/kg enoxaparin subcutaneously once daily) or control arm (40 mg enoxaparin subcutaneously once daily) upon commencement of continuous renal replacement therapy.We calculated that with 133 patients in each group, the study would have 80% power to show a 40% reduction in the relative risk of venous thromboembolism with 1 mg/kg enoxaparin, at a two-sided alpha level of 0.05. An interim analysis will be conducted after the first 67 patients have been included in each group.Enrolment began in March 2013, and will continue for two years. The primary outcome is the occurrence of venous thromboembolism. Secondary outcomes include anti-factor Xa activity, bleeding, heparin-induced thrombocytopenia, filter lifespan, length of stay, ventilator free days, and mortality. We will also monitor neutrophil gelatinase-associated lipocalin and urine volume to determine whether they can be used as prognostic factors for renal recovery. Discussion: Critically ill unit patients with acute kidney injury present a particular challenge in the provision of thromboprophylaxis. This study hopes to add to the growing evidence that the existing recommendation of 40 mg enoxaparin is inadequate and that 1 mg/kg is both safe and effective for thromboprophylaxis.In addition, the study seeks to identify predictors of renal recovery allowing for the proper utilization of resources. Trial registration: EU Clinical Trials Register: EudraCT number: 2012-004368-23, 25 September 2012.
    Full-text · Article · Jun 2014 · Trials
Show more